Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVSNASDAQ:CNTXNYSE:IBIONASDAQ:KLTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.61-3.3%$2.04$1.11▼$17.88$50.66M1.62744,234 shs371,126 shsCNTXContext Therapeutics$0.57+1.6%$0.74$0.49▼$2.75$51.36M1.86281,281 shs151,137 shsIBIOiBio$0.77-14.3%$0.88$0.64▼$6.89$12.74M0.96448,033 shs926,644 shsKLTOKlotho Neurosciences$1.54+2.7%$0.48$0.11▼$5.80$50.04M0.1830.87 million shs6.32 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio0.00%-7.21%+28.04%+47.99%-50.81%CNTXContext Therapeutics0.00%-9.02%-18.83%-25.81%-71.65%IBIOiBio0.00%-16.93%-2.77%-83.35%-66.18%KLTOKlotho Neurosciences0.00%-3.75%+714.81%+425.60%+153,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio2.2116 of 5 stars3.51.00.00.02.81.70.6CNTXContext Therapeutics2.2946 of 5 stars3.62.00.00.00.61.71.3IBIOiBio1.5678 of 5 stars3.50.00.00.01.80.00.6KLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 3.00Buy$30.251,058.12% UpsideCNTXContext Therapeutics 3.20Buy$6.00947.85% UpsideIBIOiBio 3.00Buy$4.30457.72% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IBIO, ANVS, CNTX, and KLTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.005/8/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/29/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/29/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/21/2025CNTXContext TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/9/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/ACNTXContext TherapeuticsN/AN/AN/AN/A$1.27 per shareN/AIBIOiBio$375K33.96N/AN/A$1.41 per share0.55KLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)CNTXContext Therapeutics-$26.73M-$0.31N/AN/AN/AN/A-29.78%-29.08%8/6/2025 (Estimated)IBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AKLTOKlotho Neurosciences-$6.15M-$0.36N/A∞N/AN/A-1,779.01%-275.01%N/ALatest IBIO, ANVS, CNTX, and KLTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q1 2025CNTXContext Therapeutics-$0.05-$0.05N/A-$0.05N/AN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A3/31/2025Q4 2024KLTOKlotho NeurosciencesN/A-$0.07N/A-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A10.6810.68CNTXContext TherapeuticsN/A48.8148.81IBIOiBio0.051.761.76KLTOKlotho NeurosciencesN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%CNTXContext Therapeutics14.03%IBIOiBio7.90%KLTOKlotho Neurosciences20.07%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%CNTXContext Therapeutics2.80%IBIOiBio0.58%KLTOKlotho Neurosciences26.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableCNTXContext Therapeutics789.70 million87.19 millionNot OptionableIBIOiBio10016.52 million9.82 millionN/AKLTOKlotho NeurosciencesN/A32.49 million23.82 millionN/AIBIO, ANVS, CNTX, and KLTO HeadlinesRecent News About These CompaniesContrasting Klotho Neurosciences (KLTO) and Its RivalsJune 21 at 2:51 AM | americanbankingnews.comKLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMSJune 18, 2025 | prnewswire.comKLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENTJune 16, 2025 | prnewswire.comComparing Klotho Neurosciences (KLTO) & Its PeersJune 15, 2025 | americanbankingnews.comBest Penny Stocks To Research - June 10thJune 10, 2025 | marketbeat.comKlotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?June 10, 2025 | forbes.comKlotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The MoonJune 10, 2025 | msn.comPenny Stocks To Watch Today - June 9thJune 9, 2025 | marketbeat.comPromising Small Cap Stocks Worth Watching - June 9thJune 9, 2025 | marketbeat.comKLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH TO INCREASE LONGEVITY AND HEALTHY LIFE SPAN - REPLACE A SILENCED GENE CALLED ALPHA-KLOTHO ("α-KLOTHO")June 9, 2025 | prnewswire.comNasdaq Top 5 Premarket Losers: Healthcare Triangle, Klotho Neurosciences, New Fortress Energy, NanoVibronix, MDJMMay 15, 2025 | msn.comProtein discovered that boosts lifespan, muscle, and brain power with just one doseMay 10, 2025 | earth.comKlotho: A protein that promotes healthy aging and improves longevityMay 9, 2025 | msn.comBoosting Klotho Protein Slows Aging and Enhances HealthMay 9, 2025 | neurosciencenews.comKlotho Neurosciences faces Nasdaq delisting riskApril 23, 2025 | investing.comKlotho Neurosciences to Acquire SkyBell Tech SubsidiaryApril 3, 2025 | investing.comKlotho Neurosciences, Inc. (KLTO)February 2, 2025 | ca.finance.yahoo.comKlotho Neuroscience Inc (KLTO)January 28, 2025 | investing.comKlotho Neurosciences secures $2M in convertible notes and warrantsJanuary 24, 2025 | msn.comKlotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San FranciscoJanuary 8, 2025 | globenewswire.comKlotho Neurosciences to Present at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San FranciscoJanuary 8, 2025 | prismmediawire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBIO, ANVS, CNTX, and KLTO Company DescriptionsAnnovis Bio NYSE:ANVS$2.61 -0.09 (-3.26%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$2.73 +0.12 (+4.52%) As of 06/20/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Context Therapeutics NASDAQ:CNTX$0.57 +0.01 (+1.58%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.60 +0.03 (+5.66%) As of 06/20/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.iBio NYSE:IBIO$0.77 -0.13 (-14.33%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.78 +0.01 (+1.82%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Klotho Neurosciences NASDAQ:KLTO$1.54 +0.04 (+2.67%) As of 06/20/2025 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
